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Table
Relation of smoking status and intensity to widespread pain and knee pain severity.
Widespread pain at baseline Incident widespread pain at 84-month visit Knee pain severity (WOMAC) at baseline
N(%) of knees Adjusted OR* (95% CI) N(%) of knees Adjusted OR* (95% CI) N of knees Adjusted difference in
median* (95% CI)
Smoking status
never smoker 823/1655 (49.7) 1.0 (referent) 133/643 (20.7) 1.0 (referent) 1673 0 (referent)
current smoker 106/195 (54.4) 1.0 (0.7, 1.5) 12/53 (22.6) 0.9 (0.4, 2.0) 196 0.83 (0.03, 1.63)
former smoker 596/1147 (52.0) 1.3 (1.0, 1.5)1 92/400 (23.0) 1.2 (0.9, 1.7) 1154 0.00 (0.25, 0.25)
Smoking intensity (pack-year)
0 823/1655 (49.7) 1.0 (referent) 133/643 (20.7) 1.0 (referent) 1673 0 (referent)
1-10 251/495 (50.7) 1.2 (0.9, 1.5) 36/191 (18.8) 0.9 (0.6, 1.4) 497 0.33 (0.04, 0.70)
10-29 250/481 (52.0) 1.3 (1.0, 1.6)1 38/158 (24.1) 1.3 (0.8, 2.0) 484 0.17 (0.22, 0.56)
301 201/365 (55.1) 1.2 (0.9, 1.6) 30/103 (29.1) 1.7 (1.0, 2.8) 369 0.00 (0.43, 0.43)
*Adjusting for age. sex, race, clinic, BMI, Kellgren and Lawrence grade, CES-D score, and catastrophizing; p<0.0l
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A62examined the cross-sectional association between smoking and WSP
at baseline using logistic regression, and between smoking and knee
pain severity at baseline using quantile regression with generalized
estimating equations to account for correlations between two knees
within a subject. We used the same approach to assess the effect of
baseline smoking on incident WSP. For pain sensitization outcomes,
we used logistic regression to assess the cross-sectional relation
between smoking and TS at 84-month visit, and used linear regres-
sion to assess the relation between smoking and PPT. Age, sex, race,
clinic, BMI, Kellgren and Lawrence grade of radiographic OA severity,
CES-D score, and catastrophizing were adjusted for as potential
confounders.
Results: Among 3026 subjects recruited at baseline (age mean ±; SD:
62.5 ±; 8.1, BMI mean ±; SD: 30.7 ±; 6.0 kg/m2, 60% women), 197
subjects (6.5%) were current smokers and 1155 (38.2%) were former
smokers. The median (25th, 75th percentile) smoking intensity among
smokers was 21.5 (15.0, 31.0) pack-years. The prevalence of WSP at
baseline were 50%, 55%, and 52% among never smokers, current
smokers and former smokers, with slightly higher prevalence among
former smokers compared with non-smokers (adjusted odds ratio
(95% CI) ¼ 1.3 (1.0, 1.5), p¼0.01). The risk of incident WSP at the 84-
month follow-up was similar among the three smoking status groups
(Table). While the prevalence of WSP at baseline did not differ by
smoking intensity, the risk of incident WSP increased with increasing
smoking intensity; smokers with 1-9, 10-29, 30 pack-years had odds
ratios of 0.9, 1.3 and 1.7, respectively, for risk of incident WSP com-
pared with non-smokers (p-value for linear trend ¼0.02). Knee pain
severity was higher among current smokers than non-smokers (Table),
but there was no relation to smoking intensity. The prevalence of TS at
84-month visit was 39%, and did not differ by smoking status or
intensity. Similarly, there was no difference in PPT by smoking status
or intensity.
Conclusions: Smoking intensity had a dose response relationship with
incident WSP, and current smoking was associated with knee pain
severity. No relation was observed between smoking and pain sensiti-
zation. The reasons for increased pain among smokers need further
clariﬁcation.
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TGF-b IS A POTENT INDUCER OF NERVE GROWTH FACTOR IN
ARTICULAR CARTILAGE VIA THE ALK5-SMAD2/3 PATHWAY.
POTENTIAL ROLE IN OA RELATED PAIN?
E. N. Blaney Davidson, A.P. van Caam, E.L. Vitters, M.B. Bennink,
E. Thijssen, W.B. van den Berg, M.I. Koenders, P.L. van Lent,
F.A. van de Loo, P.M. van der Kraan. Radboud Univ. Med. Ctr., Nijmegen,
Netherlands
Purpose: Pain is the main problem for patients with OA. Unfortunately,
pain relief is not effective in every individual. In general, pain is linked
to inﬂammation. However, in a subset of OA patients pain is experi-
enced without obvious inﬂammation driving the pain. This indicates
there must be an additional alternative source of pain besides inﬂam-
mation. NGF inhibition has been shown very efﬁcient in blocking pain
during OA, but the exact source of NGF is unclear. NGF is elevated in
human OA,as well as in animal models of OA with cartilage damage
without inﬂammation.TGF-beta is released from cartilage upondamage. We investigated whether TGF-beta could contribute to NGF
expression in the joint. Furthermore, we studied the speciﬁc Smad-
related TGF-beta pathways involved in this process.
Methods:Murine andhuman chondrocyte cell lines, primarybovine and
human chondrocytes, and cartilage explants from bovine metacarpal
joints and humanOA jointswere stimulatedwith TGF-b1 and/or IL-1b as
a positive control for NGF induction. We analyzed NGF expression on
mRNA level with QPCR and stained human OA cartilage for NGF immu-
nohistochemically. Cultures were additionally pre-incubated with
inhibitors for TAK1 (oxozeaenol), Smad2/3 (SB-505124) or Smad1/5/8
(LDN-193189) signaling to identify the TGF-b pathway inducing NGF.
Results: We found that TGF-beta was capable of inducing NGF
expression, even in low dosage of 1 ng/ml. NGF expression was con-
sistently induced at higher levels by TGF-b than IL-1 in all of our
experiments: murine, bovine and human origin, in cell lines, primary
chondrocytes and explants cultures. Combining TGF-beta with IL-1 did
not result in higher levels of NGF expression than those already reached
by a single dose of TGF-beta alone. As TAK1 is a common pathway
component of both IL-1 and TGF-beta signaling, we initially expected
TAK1 to be dominant and pivotal in NGF induction. TAK1 inhibition
consistently reduced (but not blocked) TGF-b-induced NGF whereas it
fully blocked IL-1b-induced NGF expression. In contrast, ALK5-Smad2/3
inhibition fully blocked TGF-b-induced NGF expression. Blocking the
Smad1/5/8 pathway with LDN did not have an effect on TGF-beta-
induced NGF. In human OA primary chondrocytes we found that there
was a large variation in basal NGF levels (mRNA and histology). Upon
stimulation with TGF-b we found a consistent higher level of NGF
induction than upon stimulationwith IL-1, which was not related to the
basal levels of NGF. In explants of human OA cartilage we observed
chondrocytes positive staining for NGF. When stimulating human OA
cartilage with TGF-beta NGF expression increased, which could be fully
blocked by inhibiting ALK5-Smad2/3 signaling.
Conclusions: This is the ﬁrst time that it is shown that TGF-b induces
NGF expression in (primary) chondrocytes. Moreover, we found that
TGF-beta consistently induced NGF at higher levels than IL-1. In addi-
tion, IL-1 induced NGF could be fully abrogated by TAK1 inhibition, but
this only had a reducing effect on TGF-beta induced NGF expression. In
contrast blocking signaling via ALK5-Smad2/3 fully abrogated the TGF-
beta-induced NGF expression. Clearly, our data show that there are
sources of NGF other than inﬂammation in the joint and that this should
be taken into account when studying pain in OA.
66
CITED2 MEDIATES CROSS-TALK BETWEEN MECHANICAL LOADING
AND IL-4 AND RESULTS IN SYNERGISTIC CHONDROPROTECTION IN
VITRO AND IN VIVO
Z. He y, D.J. Leong y, L. Xu y, J.A. Hardin y, R.J. Majeska z, M.B. Schafﬂer z,
M.M. Thi y, L. Cardoso z, M.B. Goldring x, N.J. Cobelli y, H.B. Sun y. yAlbert
Einstein Coll. of Med., Bronx, NY, USA; z The City Coll. of New York, New
York, NY, USA; xHosp. for Special Surgery, New York, NY, USA
Purpose: Interleukin (IL)-4, is an anti-inﬂammatory cytokine that
reduces pro-inﬂammatory cytokine production and activity, and might
be chondroprotective. However clinical trials using IL-4 have not been
successful due to side effects from high doses of IL-4. CITED2 (CBP/
P300-interacting transactivator 2), originally identiﬁed as an IL-4-
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A63inducible molecule in T-lymphocytes, is a critical is a transcriptional
regulator that down-regulates MMPs in response to moderate loading
in chondrocytes. In this study, we tested the hypothesis that CITED2
mediates cross-talk between IL-4 and mechanical loading resulting in
synergistic chondroprotection by, at least in part, downregulating
MMPs such as MMP-13.
Methods: C28/I2 chondrocytic cells were treated with IL-4 (R&D) at
various concentrations, uniaxial tensile strain (5%, 1Hz, 1hr), or inter-
mittent hydrostatic pressure (5MPa, 1Hz, 1hr) in the presence of IL-1b,
and/or inhibitors of Jak3, or STAT6 (Santa Cruz). Cited2 and Mmp13
mRNA levels were analyzed by real-time PCRwith GAPDH as an internal
control. Phosphorylation of Jak3 and Stat6 was analyzed by Western
blot. IL-4 knockout mice or wild-type littermates (5- to 6-months-old,
male, n¼6/group) were treated with intra-articular injection of CITED2
siRNA, 24 hours before they were subjected to moderate treadmill
running at 10 m/min for 45 min. Mice with post-traumatic OA due to
destabilization of the medial meniscus (DMM) were subject to daily
intra-injections of PBS (control), or mouse recombinant IL-4 and either
hind limb immobilization or cage activity for 4 weeks (5- to 6-months-
old, male, n¼3/group). Cartilage integrity was evaluated by histological
scoring after Safranin O staining of ﬁxed sections. Signiﬁcant differences
were determined using one-way ANOVA with Tukey post-hoc test.
Results: IL-4 induces CITED2 in C28/I2 chondrocytic cells through the
Jak/Stat pathway: CITED2 gene expression was inducible by IL-4 in a
dose-dependent manner (Fig. 1A), with a time course of peak induction
at 8 hrs, declining thereafter (Fig 1B, and associated with down-
regulated MMP-13 gene expression. Targeted screening of signaling
pathways revealed that the induction of CITED2 by IL-4 was abolished
by JAK3- or STAT6-speciﬁc inhibitors (Fig 1C). Western blotting further
demonstrated that upregulation of CITED2 was mediated by phos-
phorylation of Jak3 and STAT6 (Fig 1D).
Combination of mechanical loading and a low dose of IL-4 ampliﬁes the
downregulation of MMP-13: Moderate mechanical loading (uniaxial
strain and IHP), when combined with IL-4 (1ng/ml), elevated CITED2
mRNA to a level signiﬁcantly higher than that induced by strain or IL-4
alone (Fig 2A, 2B), to a level similar to that achieved with a high dose of
IL-4 (10ng/ml, Fig 2A). Expression of MMP-13 was inversely correlated
inversely with CITED2 expression, and most signiﬁcantly down-
regulated in response to IL-4 and loading combined (Fig 2A, 2B). The
synergistic effects of loading and IL-4 were abolished in chondrocytes
when CITED2 was knocked down by siRNA prior to the relevant treat-
ment (Fig 2C).
IL-4 and mechanical loading exert synergistic chondroprotection in
vivo: Moderate treadmill running (10 m/min, 45 min) reduced Mmp13
mRNA levels in the knee articular cartilage of wild type mice. This
reductionwas partially abolished in IL-4 knockout mice and completely
abolished in the chondrocytes when CITED2 expression was knocked
down by intra-articular injection of Cited2 siRNA in knee joints (Fig 3A).
Furthermore, while intra-articular injections of mouse recombinant IL-
4 in DMM mice without mechanical loading (i.e. with their hind limb
immobilized) resulted in better preservation of the articular cartilage
compared to mice treated with PBS, IL-4, and loading (i.e., cage activity)
exerted the highest efﬁcacy in chondroprotection (Fig 3B).
Conclusions: We demonstrated: 1) IL-4 induces CITED2 expression in
chondrocytes, which ismediated by Jak/Stat signaling; 2) IL-4 combined
with mechanical loading exerts a synergistic chondroprotection in vitro
and in vivo. This study demonstrated a proof-of-concept for a potential
OA intervention with moderate loading, through exploiting the ability
of CITED2 to amplify the anti-catabolic effect of IL-4 and prevent side
effects of high doses of this cytokine.Figure 1. IL-4 includes CITED2 mRNA expression in a (A) dose and (B)
time-dependent manner in human C28/I2 chondrocytic cells. (C) IL-4-
induced is suppressed by Jak3 and STAT6 inhibitors and (D) CITED2
upregulation is associated with phosphorylation of Jak3 and STAT6, as
revealed by real-time PCR and Western blot, respectively.Figure 2. A low dose of IL-4 combined with either (A) uniaxial tensile
strain or (B) IHP synergistically induces CITED2 mRNA and suppresses
MMP-13 mRNA. (C) These effects are abolished by CITED2 knocked down
in C28/I2 chondrocytes transfected with CITED2 siRNA in the presence of
IL-1b.
Figure 3. (A) Moderate treadmill running-suppressed Mmp-13 expression
in the articular cartilage is diminished in IL4KO mice and completely
abolished in IL4KO mice with Cited2 knocked down. (B) DMM mice
subjected to IL-4 and cage activity (cage) exhibited efﬁcacy in chon-
droprotection The chondroprotective effect was diminished in DMM þ IL-
4 mice when the hind limb was immobilized (Imm, deloading). White
arrows indicate regions cartilage erosion or loss of proteoglycans.
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JNK2 KNOCKOUT MICE ARE SIGNIFICANTLY PROTECTED FROM
SURGICALLY INDUCED OSTEOARTHRITIS
H.M. Ismail, J. Zarebska, T. Vincent, J. Saklatvala. Kennedy Inst. of
Rheumatology, Univ. of Oxford, Oxford, United Kingdom
Purpose: The pathogenesis of osteoarthritis (OA) is poorly understood.
The earliest event is loss of the proteoglycan aggrecan from the car-
tilage matrix. Recently, we identiﬁed a signiﬁcant role for the JNK
pathway particularly JNK2 in regulation of aggrecan degradation by
human articular chondrocytes in vitro. To understand whether JNK2
plays a role maintaining cartilage integrity in vivo, we investigated the
development of osteoarthritis in JNK2 knockout mice using destabi-
lizing the medial meniscus OA surgical model (DMM). The role of JNK2
in inﬂammatory gene expression induced by DMM was also
investigated.
Methods: We ﬁrst compared the IL-1 responses of hip cartilage from
JNK2 knockout and wild-type C57BL6 mice. Proximal femoral epiphyses
were cultured in the presence or absence of IL-1. Aggrecan fragments
were analysed in the conditioned media by western blotting. OA was
induced by surgically destabilising the medial meniscus (DMM). Ani-
mals were sacriﬁced after 4, 8 and 12 weeks and sections taken through
the knees were stained with Safranin O. The medial compartments of
the knees were scored by a validated histological grading system for
aggrecan loss and cartilage damage. To test the effect of JNK2 deﬁciency
on inﬂammatory gene regulation, RNA was extracted from JNK2
knockout and wildtype knees 6hrs following DMM. Gene expression
proﬁles of 48 DMM-regulated genes (previously reported by our group)
were analysed by q-PCR using customized Taqman Low Density Array
(TLDA) cards.
Results: IL-1 failed to generate aggrecanase-mediated aggrecan frag-
ments in the JNK2 knockout cartilage compared with wild type con-
trols. The JNK2 knockout animals showed signiﬁcant reduction of
cartilage damage at all time points compared with wild-type operated
animals, indicating that activity in the JNK pathway contributes to
aggrecan loss and cartilage damage in vivo. Of the 48 genes inves-
tigated, 12 genes were signiﬁcantly down-regulated in JNK2 knockout
mice following DMM compared with wildtype controls. This panel of
